Research programme: thrombin inhibitors - Santhera Pharmaceuticals

Drug Profile

Research programme: thrombin inhibitors - Santhera Pharmaceuticals

Alternative Names: GRA 184314; Thrombin inhibitors research programme - Santhera Pharmaceuticals

Latest Information Update: 12 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Santhera Pharmaceuticals
  • Class
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 12 Mar 2008 Discontinued - Preclinical for Thrombosis in Germany (unspecified route)
  • 13 Sep 2004 MyoContract has merged with Graffinity Pharmaceuticals to form Santhera Pharmaceuticals
  • 29 Mar 2004 This programme is available for licensing worldwide (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top